KCC1 Inhibitors, though not directly targeting the Potassium-Chloride Cotransporter 1 (KCC1), encompasses a variety of compounds primarily influencing ion transport and homeostasis in cellular environments. This class includes diverse groups such as loop diuretics, thiazide diuretics, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, and sodium-glucose transport inhibitors. The unifying theme across these compounds is their indirect modulation of ionic balances within cells, which can potentially impact the function of KCC1. For instance, loop diuretics like Furosemide and Torasemide target the NKCC cotransporters, leading to altered chloride transport dynamics, closely associated with KCC1's role in maintaining chloride and potassium equilibrium. Thiazide diuretics such as Hydrochlorothiazide affect sodium chloride transport, which can indirectly influence the cellular conditions governed by KCC1. The variations in the chemical structures and properties within this class are substantial, given the diverse mechanisms through which these compounds interact with ion transport processes.
Compounds like Valsartan, a member of the angiotensin II receptor blocker family, and Eplerenone or Spironolactone, which are mineralocorticoid receptor antagonists, contribute to the modulation of ion transport and fluid balance within cells, impacting the ionic landscape where KCC1 operates. On the other hand, sodium-glucose transport inhibitors such as Dapagliflozin, Canagliflozin, and Empagliflozin, work by inhibiting SGLT proteins, thereby affecting the sodium balance, which in turn can influence the activity of KCC1. The diverse chemical structures in this class, ranging from complex ring systems to linear molecules, reflect the variety of molecular interactions they engage in to influence ion transport. The specificity and selectivity of these compounds for their primary targets are a hallmark of their chemical nature, yet their indirect impact on KCC1 function is a consequence of the interconnected nature of cellular ion transport mechanisms. This chemical class exemplifies how alterations in one aspect of cellular homeostasis can cascade to affect related transport systems, demonstrating the intricate balance maintained within cellular environments.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Furosemide | 54-31-9 | sc-203961 | 50 mg | $40.00 | ||
A loop diuretic inhibiting NKCC (sodium-potassium-chloride cotransporter), potentially affecting KCC1 indirectly by altering chloride transport. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $107.00 $224.00 | 9 | |
Inhibits NKCC1 and NKCC2, potentially influencing KCC1 activity through changes in cellular ion balance. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $54.00 $235.00 $326.00 $551.00 $969.00 | ||
A thiazide diuretic affecting sodium chloride transport, could indirectly impact KCC1 activity. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $39.00 $90.00 $120.00 | 4 | |
An angiotensin II receptor blocker, influencing ion transport and possibly impacting KCC1 indirectly. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Inhibits epithelial sodium channels, potentially altering the ionic environment relevant to KCC1 function. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $107.00 | 3 | |
A potassium-sparing diuretic, which may affect KCC1 by altering potassium balance in cells. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $108.00 $612.00 | 4 | |
Selectively inhibits the mineralocorticoid receptor, potentially impacting KCC1 indirectly via ion homeostasis. | ||||||
Triamterene | 396-01-0 | sc-213103A sc-213103 | 1 g 5 g | $22.00 $53.00 | ||
A potassium-sparing diuretic, could influence KCC1 activity by altering intracellular potassium levels. | ||||||
Dapagliflozin | 461432-26-8 | sc-364481 sc-364481A sc-364481B | 5 mg 50 mg 1 g | $115.00 $420.00 $1030.00 | 6 | |
Inhibits sodium-glucose transport proteins, potentially affecting KCC1 by altering cellular ionic conditions. | ||||||
Canagliflozin | 842133-18-0 | sc-364454 sc-364454A | 5 mg 50 mg | $306.00 $408.00 | 2 | |
Another inhibitor of sodium-glucose transporters, may impact KCC1 indirectly. | ||||||